|
KMID : 1140420200290020099
|
|
Journal of Obesity & Metabolic Syndrome
2020 Volume.29 No. 2 p.99 ~ p.109
|
|
|
Current Long-Term Pharmacotherapies for the Management of Obesity
|
|
Kim Bo-Yeon
Kang Seon-Mee
Kang Jee-Hyun
Kim Kyoung-Kon
Kim Bom-Taeck
Kim Seung-Jun
Kim Yang-Hyun
Kim Jung-Hwan
Kim Jae-Hyun
Nam Ga-Eun
Park Ji-Yeon
Son Jang-Won
Shin Hye-Jung
Oh Tae-Jung
Lee Hyug
Jeon Eon-Ju
Chung So-Chung
Hong Yong-Hee
Kim Chong-Hwa
|
|
|
Abstract
|
|
|
|
Obesity is a serious and growing worldwide health challenge associated with type 2 diabetes mellitus, cardiovascular disease, osteoarthritis, some cancers, sleep apnea, asthma, and nonalcoholic fatty liver. The Korean Society for the Study of Obesity recommends that pharmacotherapy should be considered when intensive lifestyle modifications fail to achieve a weight reduction in obese patients with a body mass index ≥25 kg/m2. Long-term medications for obesity have traditionally fallen into two major categories: centrally acting anorexiant medications and peripherally acting medications, such as orlistat. In this paper, we provide an overview of the anti-obesity medications currently available for the long-term and individualized treatment of obesity.
|
|
|
KEYWORD
|
|
|
Obesity, Orlistat, Lorcaserin, Liraglutide, Naltrexone/bupropion extended-release, Phentermine/topiramate extended-release
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|